Showing 9,521 - 9,540 results of 18,405 for search 'significantly ((((we decrease) OR (((a decrease) OR (nn decrease))))) OR (observed decrease))', query time: 0.59s Refine Results
  1. 9521

    Table 1_Diverging trends in the global burden of ischemic heart disease attributable to non-optimal temperatures: a historical analysis (1990–2021) and 2050 projections.docx by Zehao Jin (11408687)

    Published 2025
    “…Significant socioeconomic disparities were observed, with low-to-middle SDI regions bearing a disproportionate share (75.0%) of the global high non-optimal temperature-related mortality burden. …”
  2. 9522

    Supplementary tables: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

    Published 2025
    “…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”
  3. 9523

    Data Sheet 1_Glucocorticoids and immunoglobulin alone or in combination in the treatment of multisystemic inflammatory syndrome in children: a systematic review and network meta-an... by Junjie Lin (8379594)

    Published 2025
    “…When compared to combination therapy, GCs monotherapy was associated with a reduction in ICU length of stay [SMD −0.25, 95% CI (−0.85, 0.36)], duration of fever (SMD [−0.42, 95% CI (−0.73, −0.11)], and duration of inotropic support [SMD −0.13, 95% CI (−0.46, 0.20)], as well as a decrease in the incidence of left ventricular (LV) dysfunction [OR 0.96, 95% CI (0.55, 1.68)]. …”
  4. 9524

    Supplementary data: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

    Published 2025
    “…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”
  5. 9525

    Table 1_Has carbon finance been able to promote clean energy development? — a low-carbon technology innovation perspective.xlsx by Rui Cui (622759)

    Published 2025
    “…It is found that carbon finance significantly promotes clean energy development, but this contribution decreases with the intervention of low-carbon technology innovation. …”
  6. 9526

    Data Sheet 1_Effectiveness of community-based management models in chronic obstructive pulmonary disease: a systematic review and meta-analysis.docx by Miao Zhan (2625718)

    Published 2025
    “…Notably, neither approach demonstrated a statistically significant advantage in improving quality of life among COPD populations, as assessed by the St. …”
  7. 9527
  8. 9528

    Image 3_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.jpeg by Stephen Mwangi Kamau (20576060)

    Published 2025
    “…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”
  9. 9529

    Table 1_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.xlsx by Stephen Mwangi Kamau (20576060)

    Published 2025
    “…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”
  10. 9530

    Image 1_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.jpeg by Stephen Mwangi Kamau (20576060)

    Published 2025
    “…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”
  11. 9531

    Image 2_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.jpeg by Stephen Mwangi Kamau (20576060)

    Published 2025
    “…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”
  12. 9532

    DataSheet1_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

    Published 2024
    “…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”
  13. 9533

    DataSheet2_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

    Published 2024
    “…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”
  14. 9534

    DataSheet3_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

    Published 2024
    “…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”
  15. 9535
  16. 9536

    Home-based strength and balance exercises for fall prevention among older individuals of advanced age: a randomized controlled single-blind study by Jian Zhou (28020)

    Published 2025
    “…The composite equilibrium score (SOTcom) for vestibular and integrated balance on the Sensory Organization Test (SOT) increased in the test group, while SOTcom decreased in the control group. In the test group, there was a significant improvement in the indexes pertaining to response time, movement speed, directional control, and endpoint offset in some directions. …”
  17. 9537

    Image 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.jpeg by Xin Fei (20466992)

    Published 2024
    “…The patient was then administered a combination of anlotinib and tislelizumab. After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”
  18. 9538

    Supplementary Material for: Delayed Onset of Central Serous Chorioretinopathy (CSCR) following corticosteroid treatment for Giant Cell Arteritis (GCA): A Case Report by figshare admin karger (2628495)

    Published 2025
    “…Although the association between CSCR and corticosteroids is well established, its occurrence in patients diagnosed with GCA remains rarely reported in literature. Case Presentation: We present a case of a 71-year-old man who developed CSCR following six months of corticosteroid treatment for GCA. …”
  19. 9539

    Table 3_Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021.xlsx by Zhixun Bai (14021787)

    Published 2025
    “…Background<p>Acute viral hepatitis (AVH) remains a global health concern, with significant variations in incidence, mortality, and DALYs across different regions, age groups, genders, and socioeconomic levels. …”
  20. 9540

    Table 2_Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021.xlsx by Zhixun Bai (14021787)

    Published 2025
    “…Background<p>Acute viral hepatitis (AVH) remains a global health concern, with significant variations in incidence, mortality, and DALYs across different regions, age groups, genders, and socioeconomic levels. …”